[SPS 2022] Integrated Cardiac Proarrhythmic Risk Assessment Using Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes
- Version:
- 21369
- File Name/Number:
- SPS
- Year:
- 2022
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is an effort to improve the accuracy of proarrhythmic risk assessment by reducing the focus on in vitro hERG channel assays and in vivo QT interval measurements.